Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of rapcabtagene autoleucel in refractory active systemic lupus erythematosus or active lupus nephritis
MOH_2026-01-05_015586Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (4 cohorts), sponsored by Novartis. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on MOH_2026-01-05_015586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-05_015586.